SCHEMBL4036919

SCHEMBL4036919

CCCCNC(=O)C(c1ccc(OC)cc1)C1(c2cccc(OC)c2OC)Nc2ccccc2N1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
HSD17B10 Q99714 1/20 0.37
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 3/20 0.36
TSHR P16473 1/20 0.36
CTSD P07339 2/20 0.36
ALDH1A1 P00352 3/20 0.36
PTPN1 P18031 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040091 0.94 LMNA (0.40) HPGDNPSR1TSHRCTSD
SCHEMBL4043634 0.87 CTSD (0.42) CNR1CNR2HSD17B10CTSDALDH1A1
SCHEMBL4043313 0.85 TSHR (0.38) HPGDNPSR1TSHR
SCHEMBL4043642 0.83 CTSD (0.46) CNR1CNR2NPSR1CTSDALDH1A1
SCHEMBL4036859 0.82 CTSD (0.40) CTSDALDH1A1PTPN1
SCHEMBL4038953 0.81 HCRTR1 (0.43) TSHRCTSDALDH1A1PTPN1
SCHEMBL4039204 0.79 TSHR (0.43) HPGDNPSR1TSHRALDH1A1SMN1; SMN2
SCHEMBL4039555 0.76 USP2 (0.38) NPSR1ALDH1A1SMN1; SMN2
SCHEMBL4037816 0.76 HPGD (0.38) HPGDTSHRALDH1A1SMN1; SMN2
SCHEMBL4044341 0.75 C5AR1 (0.40) CTSDALDH1A1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed